Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Average Rating of “Moderate Buy” by Analysts

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has received a consensus recommendation of “Moderate Buy” from the twelve brokerages that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, eight have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $87.80.

A number of research analysts have recently weighed in on ARWR shares. Sanford C. Bernstein raised their price objective on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. Wall Street Zen cut shares of Arrowhead Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. HC Wainwright reissued a “buy” rating and set a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, March 25th. Weiss Ratings cut shares of Arrowhead Pharmaceuticals from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Wednesday, May 20th. Finally, JPMorgan Chase & Co. started coverage on shares of Arrowhead Pharmaceuticals in a research note on Friday, May 1st. They set an “overweight” rating and a $88.00 price objective for the company.

Insiders Place Their Bets

In other Arrowhead Pharmaceuticals news, Director Hongbo Lu sold 2,970 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total value of $228,333.60. Following the completion of the sale, the director directly owned 52,012 shares of the company’s stock, valued at approximately $3,998,682.56. The trade was a 5.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider James C. Hamilton sold 10,000 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Thursday, April 23rd. The stock was sold at an average price of $75.00, for a total transaction of $750,000.00. Following the completion of the sale, the insider directly owned 226,958 shares of the company’s stock, valued at $17,021,850. The trade was a 4.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 36,065 shares of company stock valued at $2,554,562. Company insiders own 3.60% of the company’s stock.

Institutional Trading of Arrowhead Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. CWM LLC grew its stake in Arrowhead Pharmaceuticals by 1.4% in the 4th quarter. CWM LLC now owns 12,347 shares of the biotechnology company’s stock worth $820,000 after acquiring an additional 168 shares during the period. First Horizon Corp grew its stake in shares of Arrowhead Pharmaceuticals by 36.3% during the 1st quarter. First Horizon Corp now owns 654 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 174 shares during the period. PNC Financial Services Group Inc. grew its stake in shares of Arrowhead Pharmaceuticals by 1.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 11,102 shares of the biotechnology company’s stock valued at $737,000 after buying an additional 178 shares during the period. HighTower Advisors LLC grew its stake in shares of Arrowhead Pharmaceuticals by 0.3% during the 4th quarter. HighTower Advisors LLC now owns 133,229 shares of the biotechnology company’s stock valued at $8,845,000 after buying an additional 340 shares during the period. Finally, Maryland State Retirement & Pension System grew its stake in shares of Arrowhead Pharmaceuticals by 1.8% during the 4th quarter. Maryland State Retirement & Pension System now owns 20,241 shares of the biotechnology company’s stock valued at $1,344,000 after buying an additional 365 shares during the period. 62.61% of the stock is owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Trading Down 3.5%

Shares of ARWR opened at $75.20 on Tuesday. The company has a debt-to-equity ratio of 1.41, a current ratio of 6.23 and a quick ratio of 6.23. The firm has a 50 day simple moving average of $69.93 and a 200-day simple moving average of $64.81. Arrowhead Pharmaceuticals has a 1-year low of $14.30 and a 1-year high of $82.26. The stock has a market cap of $10.59 billion, a price-to-earnings ratio of -34.98 and a beta of 1.28.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The business had revenue of $73.74 million during the quarter, compared to analysts’ expectations of $73.84 million. During the same period last year, the company posted $2.75 EPS. The company’s revenue was down 86.4% on a year-over-year basis. Equities analysts forecast that Arrowhead Pharmaceuticals will post -2.98 EPS for the current fiscal year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.